Replies to post #180755 on Biotech Values

[DewDiligence]

EVGN now below its [US] IPO price of $14.75. Wondering out loud how much is business related and how much is conflict related?

Doubtful that EVGN’s share price has been materially effected by recent political and military actions. Rather, EVGN is simply a biotech company in a low period for investor excitement while it awaits its first product launch and potential profitability in 2016 (#msg-99109422). Moreover, EVGN does not have much buyout vig, for the reason mentioned in #msg-99101253.